NNZ-2591 as a Treatment for Angelman Syndrome

Explore the potential of NNZ-2591 as a treatment for Angelman syndrome. Learn about Neuren Pharmaceuticals’ clinical trials, preclinical studies, and the drug’s neurobiological properties.

Fireside Chat: The FAST Commercial Philosophy

Join Alana Newhouse and Ryan Jacob as they discuss FAST’s commercial philosophy, the importance of partnerships, and the challenges in the rare disease community. Discover the balance between communication and commercialization.

FAST Roadmap to a C.U.R.E. 2.0

Join Allyson Berent at the 2022 FAST Science Summit as she discusses the roadmap to a C.U.R.E. 2.0 for Angelman Syndrome and the science behind it. Be part of the movement!